Equillium Inc. (EQ)
EQ trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.32
-12.00% on the day
Market cap
$83.7M
Micro cap
Revenue · 2024
$41.1M
+13.9% on 2023
Net income · 2024
-$8.1M
-19.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2024.
Profile
| Field | Value |
|---|---|
| Ticker | EQ on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001746466 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $41.1M |
| Net income | -$8.1M |
| Operating income | -$8.3M |
| Net margin | -19.6% |
| Operating margin | -20.1% |
| Revenue growth | +13.9% |
| Cash | $18.1M |
| Total assets | $25.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-04-07 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-10-05 |
| Latest proxy | DEFA14A | 2026-04-15 |
Source: SEC EDGAR submissions feed, 463 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TELO | Telomir Pharmaceuticals Inc. | $1.09 | -0.91% | $80.2M |
| AARD | Aardvark Therapeutics Inc. | $4.04 | -9.21% | $88.4M |
| RLYB | Rallybio Corporation | $16.72 | -0.42% | $88.8M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $8.66 | -8.36% | $77.7M |
| RFL | Rafael Holdings Inc. | $1.49 | -1.97% | $77.5M |
| NTHI | NeOnc Technologies Holdings Inc. | $2.60 | -4.95% | $77.2M |
| BMEA | Biomea Fusion Inc. | $1.26 | -7.35% | $91.3M |
| RTSN | Retension Pharmaceuticals Inc. | $11.63 | +2.74% | $91.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier